JP2023515806A - 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物 - Google Patents

免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物 Download PDF

Info

Publication number
JP2023515806A
JP2023515806A JP2022550673A JP2022550673A JP2023515806A JP 2023515806 A JP2023515806 A JP 2023515806A JP 2022550673 A JP2022550673 A JP 2022550673A JP 2022550673 A JP2022550673 A JP 2022550673A JP 2023515806 A JP2023515806 A JP 2023515806A
Authority
JP
Japan
Prior art keywords
cells
arginine
car
cell
transporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515806A5 (https=
Inventor
クウォク ミン チュン，
Original Assignee
スカイ パーフェクト インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スカイ パーフェクト インターナショナル リミテッド filed Critical スカイ パーフェクト インターナショナル リミテッド
Publication of JP2023515806A publication Critical patent/JP2023515806A/ja
Publication of JP2023515806A5 publication Critical patent/JP2023515806A5/ja
Priority to JP2026005807A priority Critical patent/JP2026063215A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022550673A 2020-02-21 2021-02-20 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物 Pending JP2023515806A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026005807A JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979805P 2020-02-21 2020-02-21
US62/979,805 2020-02-21
PCT/CN2021/077002 WO2021164753A1 (en) 2020-02-21 2021-02-20 Methods and compositions for modulating arginine levels in immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026005807A Division JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Publications (2)

Publication Number Publication Date
JP2023515806A true JP2023515806A (ja) 2023-04-14
JP2023515806A5 JP2023515806A5 (https=) 2024-02-29

Family

ID=77390457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022550673A Pending JP2023515806A (ja) 2020-02-21 2021-02-20 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物
JP2026005807A Pending JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026005807A Pending JP2026063215A (ja) 2020-02-21 2026-01-16 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物

Country Status (13)

Country Link
US (1) US20230265386A1 (https=)
EP (1) EP4107254A4 (https=)
JP (2) JP2023515806A (https=)
KR (1) KR20220157396A (https=)
CN (1) CN115427553A (https=)
AR (1) AR121392A1 (https=)
AU (1) AU2021223138A1 (https=)
BR (1) BR112022016571A2 (https=)
CA (1) CA3171901A1 (https=)
IL (1) IL295606A (https=)
MX (1) MX2022010280A (https=)
TW (1) TW202144569A (https=)
WO (1) WO2021164753A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
CN114788870B (zh) * 2022-04-29 2023-06-06 浙江大学 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用
WO2026063691A1 (ko) * 2024-09-20 2026-03-26 삼성바이오에피스 주식회사 아르기니노숙시네이트 합성효소를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122936A1 (en) * 2017-12-22 2019-06-27 Cancer Research Technology Limited Fusion proteins
JP2019533676A (ja) * 2016-10-13 2019-11-21 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533676A (ja) * 2016-10-13 2019-11-21 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
WO2019122936A1 (en) * 2017-12-22 2019-06-27 Cancer Research Technology Limited Fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUR. J. IMMUNOL., vol. 46, JPN6025011268, 2016, pages 92 - 103, ISSN: 0005687837 *
GENE THERAPY, vol. 21, JPN6025011271, 2014, pages 533 - 538, ISSN: 0005555930 *
INTERNATIONAL JOURNAL OF CANCER, vol. 145, JPN6025011269, 2019, pages 2201 - 2208, ISSN: 0005555929 *

Also Published As

Publication number Publication date
CN115427553A (zh) 2022-12-02
TW202144569A (zh) 2021-12-01
AR121392A1 (es) 2022-06-01
CA3171901A1 (en) 2021-08-26
MX2022010280A (es) 2022-11-16
AU2021223138A1 (en) 2022-09-29
EP4107254A1 (en) 2022-12-28
IL295606A (en) 2022-10-01
BR112022016571A2 (pt) 2022-11-16
WO2021164753A1 (en) 2021-08-26
US20230265386A1 (en) 2023-08-24
KR20220157396A (ko) 2022-11-29
EP4107254A4 (en) 2024-08-14
JP2026063215A (ja) 2026-04-10

Similar Documents

Publication Publication Date Title
JP7157839B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
TWI904120B (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
US20230340113A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
US12275787B2 (en) Chimeric antigen receptors (CARs), compositions and methods thereof
JP2022191241A (ja) ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
AU2022202024A1 (en) Treatment of cancer using humanized anti cd19 chimeric antigen receptor
JP6541639B2 (ja) Ｔ細胞増殖をコントロールするための方法
JP2026063215A (ja) 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物
CA3084190A1 (en) Methods for enhancing and maintaining car-t cell efficacy
WO2024118559A2 (en) Engineered immune cells for treating disorders, compositions and methods thereof
EP3986443A1 (en) Combination cancer immunotherapy
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
EP4646227A1 (en) Antigen recognizing receptors targeting l1cam and uses thereof
WO2024227145A1 (en) Enhanced fusion polypeptide for immunotherapy
IL323010A (en) Secondary CAR production for tumor therapy
CN118369332A (zh) 靶向cd33的抗原识别受体和其用途
CA3189328A1 (en) Chimeric tim receptors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250916